Clinical Study on the Safety of Bevacizumab in the Treatment of Patients with Advanced Colorectal Cancer

赵磊,王婧,车娟娟,李卉惠,曹邦伟

DOI: https://doi.org/10.16252/j.cnki.issn1004-0501-2018.02.038

2018-01-01

Abstract:Objective To study the safety of bevacizumab in the treatment of colorectal cancer,in order to provide some guidance for the clinical application.Methods A retrospective analysis of 72 patients with advanced colorectal cancer who were admitted to our hospital and treated with bevacizumab was conducteol.Adverse reactions and incidence of bevacizumab were col-lected.A single variable and multivariate analysis was used to determine the potential risk factors for the adverse reactions of bev-acizumab.Results A total of 72 patients were evaluable for safety.The most common adverse drug reactions were hypertension (12.5%),hemorrhage(12.5%),and proteinuria(8.3%).The incidence of serious adverse drug reactions was low: the inci-dence of bleeding was 1.4 %,the incidence of venous thromboembolism was 1.4 %,and the incidence of gastrointestinal perfora-tion was 1.4 %.The high risk factors of adverse drug reactions were identified by multivariate analysis.Conclusion Bevacizumab has a low incidence of serious adverse events.Patients with advanced or metastatic colorectal cancer have better safety and better tolerance to bevacizumab.